Pulse Biosciences (NASDAQ:PLSE) used its fourth-quarter and full-year 2025 earnings call to outline progress across its ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to ...
1d
Pulse Biosciences targets CE Mark submission in 2026 as nPulse platform advances clinical milestones
Q4 2025 earnings call: nsPFA clinical/regulatory timeline, Vybrance rollout, revenue trends, cash burn & outlook—read now.
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2025 Earnings Call Transcript February 20, 2026 Operator: Ladies and gentlemen, thank you for standing by. My name is Colby, and I will be your conference ...
Pulse BioSciences’ CTO knows what it takes to create successful medtech and sometimes, it takes partnering with the competition.
Analysts anticipate Pulse Biosciences to report an earnings per share (EPS) of $-0.25. The announcement from Pulse ...
Pulse Biosciences Inc. reports fourth-quarter and full-year 2025 results after the close Thursday, giving investors their first look at business fundamentals following a clinical data release that ...
Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.
Pulse Biosciences, Inc. , developer of the novel nPulsetm technology using proprietary Nanosecond Pulsed Field Ablationtm ...
Harmonic Inc. today announced its unaudited results for the fourth quarter and fiscal year ended December 31, 2025. "We ended ...
In a report released yesterday, Anthony Petrone from Mizuho Securities maintained a Buy rating on Glaukos. The company’s shares closed yesterday at $121.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results